BioCentury

The leading voice for decision-makers throughout the global biopharma ecosystem. Follow us on LinkedIn for exclusive insights & analysis:

[BioCentury @BioCentury]

BioCentury's latest biopharma management roundup: Song among trio of new partners at Venrock. Plus: moves at Sanofi, Biogen, Roche and more https://t.co/5RmDaBnxX1

[BioCentury @BioCentury]

Hub 101: Taiwan biotech looks to level up. Four companies show how Taiwan is combining global ambition, local capital, and technology strengths to build a biotech hub https://t.co/vjA5rtY9kj

[BioCentury @BioCentury]

EMA’s CHMP backs two orphan drugs, rebuffs FDA-approved NPC therapy. Among eight positive opinions, Minoryx’s cALD therapy wins backing after a 2024 rejection. https://t.co/pjkj0fC9ab

[BioCentury @BioCentury]

In BioCentury's Public Equity Report: Scribe's upsized IPO; Freenome, Mentari draw PIPEs during reverse mergers; Dyne's follow-on; and more https://t.co/PtiPfLYGg1

[BioCentury @BioCentury]

Mapping AI giants’ bets across the biopharma tech stack. BioCentury looks at where Anthropic, NVIDIA, Google, OpenAI and Amazon’s recent life science releases fit within biopharma R&D workflows, and with each other. https://t.co/ktUvqfFyvz

[BioCentury @BioCentury]

BioCentury's latest Science Spotlight includes several host-directed antiviral papers from China and a Stanford-MD Anderson bivalent molecular glue collab with Deep Origin https://t.co/4diY2R5lWF

[BioCentury @BioCentury]

In BioCentury's Venture Report: Crossovers join Crystalys' $130m series B to drive gout treatment's development; Iceland-based Synaptiq spins out; Dimension's new fund; and more https://t.co/2h74yYn7wn

[BioCentury @BioCentury]

Dosing, liver profile may differentiate Arrowhead in severe hypertriglyceridemia. Phase III data suggest little differentiation in efficacy versus Ionis’ Tryngolza, but Redemplo could offer advantages in dosing and hepatic safety https://t.co/Jvi6Cxb3WS

[BioCentury @BioCentury]

Initiate’s Owens on early funding and what it takes to be AI-native. On The BioCentury Show, founding Partner Jessica Owens details firm’s strategy, how proprietary data beats proprietary models, and gaps in evidence generation https://t.co/7qizNEFBIE

[BioCentury @BioCentury]

Former Black Diamond CEO David Epstein passes away; a biotech executive and professor gifted with “rare scientific intuition" https://t.co/GMoPpd7Iib

[BioCentury @BioCentury]

At oral arguments, judge seemed sympathetic to some of WuXi AppTec's arguments, but was hard to read on a critical issue. Judge Boasberg said he will rule within a couple of weeks. https://t.co/j8DJg0sm5W

[BioCentury @BioCentury]

2026 catalysts: first-half scorecard. RNA, other new modalities and cardiorenal programs largely delivered in 1H26, despite uneven antisense performance https://t.co/udpgRqDqfh

[BioCentury @BioCentury]

Series A rounds grew more concentrated in 1H26. Median series A round size rose to a decade’s high of $29.1M despite low deal count in the first half. https://t.co/5zw6GBxnFw

[BioCentury @BioCentury]

As more biotechs join the IPO queue, new listings in the next few weeks could meet or surpass a level of activity last seen in late April https://t.co/ATLnHutpAR

[BioCentury @BioCentury]

In BioCentury's Deals Report: With $132M in fresh cash from an investor syndicate, Jasper and Kira will merge and advance programs from each company's pipeline; plus, TempusAI buys Personalis; Bora/Insilico; AZ/Dizal; and more https://t.co/GgDfHxPEAC

[BioCentury @BioCentury]

WuXi AppTec says DoD used 'demonstrably false' data, incl. overstating a fund's stake by more than 5,000 times, to label it a Chinese military company. https://t.co/XwRoqNZkmw

[BioCentury @BioCentury]

Patrick Vallance is out as Minister of Science - a blow to UK biotech, which loses a big champion and force for good for the sector. John Healey is Chancellor though, likely to be seen favorably compared with the Ed Miliband option they feared. https://t.co/ZjdAmpYYNY

[BioCentury @BioCentury]

Axiom’s newborn survival signal, GSK’s chronic cough setback, and more. BioCentury's Clinical Report for July 14 – 20 https://t.co/78XhdWDApl

[BioCentury @BioCentury]

The U.K. is upping its data offering to researchers far beyond UK Biobank with HDRS -- a single front door for researchers to access NHS data from across the country https://t.co/7BagDWIXcU

[BioCentury @BioCentury]

Seed and series A biotech bets consolidated in 1H26. Early-stage venture rounds in 1H26 were fewer and farther between, but median round size neared decades’ high. https://t.co/coz5b1CclA